1. TCL-276 Outcome of NK/T-Cell Lymphoma – Retrospective Analysis from a Tertiary Care Cancer Center
- Author
-
Akhil, Rajendra, Manju, Sengar, Avinash, Bonda, Hasmukh, Jain, Lingaraj, Nayak, Sridhar, Epari, Tanuja, Shet, Jayashree, Thorat, Bhausaheb, Bagal, Archi, Agarwal, Venkatesh, Rangarajan, Vasu, Babu, and Sumeet, Gujral
- Subjects
Adult ,Male ,Cancer Research ,Tertiary Healthcare ,Hematology ,Lymphoma, Extranodal NK-T-Cell ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Asparaginase ,Humans ,Anthracyclines ,Female ,Neoplasm Recurrence, Local ,Retrospective Studies - Abstract
Extra-nodal natural killer (NK)/T-cell lymphoma is a rare, distinctive clinicopathologic entity with an aggressive clinical course. High expression of multidrug-resistant (MDR) P-gp on NK lymphoma cells renders this disease resistant to anthracycline-based chemotherapy regimens. Over the years, based on retrospective analysis and phase II studies, regimens with L-asparaginase and non-MDR drugs have been used.To evaluate the outcome of patients with extra-nodal NK/T-cell lymphoma treated in a tertiary cancer care center in India from 2012 to 2021.Retrospective, observational, single-center study.Hematolymphoid Department, Tata Memorial Hospital.From January 2010 to December 2021, all consecutive patients with NK/T-cell lymphoma were analyzed.Relapse-free survival and overall survival.A total of 78 patients with a diagnosis of extra-nodal NK/T-cell lymphoma were treated from 2010 to 2021. Amongst them, 56 (71.8%) were male, with a median age of 40 years (15-71 years). The most common presenting symptom was nasal swelling (9%), followed by dysphagia (3.8%). B symptoms were present in 35 patients (45%). Only 5% had HLH anytime during the treatment. One-third of the patients had an ECOG performance status1. Nasal type constituted 80% of the cohort, regional node was involved in 60%, distant node was involved in 28%, 33% had more than 1 extra-nodal site involved, 23% had bulky disease, and 40% had advanced stage (stage 3-4) at presentation. EBV LMP1 was positive in 19 patients (24%). EBERISH was available in 9 patients, of which 7 were positive. Fifteen patients received treatment prior to presentation to our center (CHOP in 10 patients). At our center, the SMILE chemotherapy protocol was administered to 52 patients (66.7%). Consolidative radiation therapy was administered in 43 patients (55.1%). The best radiological response of CR was achieved in 49 patients (62.8%). After a median follow-up of 30 months, 30 (38.5%) patients relapsed and 30 (38.5%) died. Median relapse-free survival was 45 (95%CI: 5.1-84.8) months. Overall survival at 36 months was 53.4% (95%CI: 41.7%-68.4%).The outcome of NK/T-cell lymphoma in our cohort is comparable to the outcomes found in the literature.
- Published
- 2022
- Full Text
- View/download PDF